Compare Alliant Energy Corporation (LNT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Alliant Energy Corporation trades at $72.68 (market cap $19.10B), while Regeneron Pharmaceuticals Inc trades at $671.56 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.7× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| LNT | REGN | |
|---|---|---|
Market Cap | $19.10B | $70.47B |
Sector | Utilities | Health |
52-Week High | $78.03 | $812.27 |
52-Week Low | $63.62 | $545.46 |
Enterprise Value | $30.83B | $64.42B |
Dividend Yield | 2.89% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $73.96, down 1.16% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $78.50. The company reported Q1 2026 EPS of $0.82, beating expectations, and maintains a net income margin of 18.58%. Recent news highlights its $13.4 billion clean energy investment plan aimed at capitalizing on data center demand growth.
The outlook for LNT is positive, supported by steady earnings growth, a strong dividend yield, and strategic investments in renewable energy. Key risks include rising debt levels and exposure to regulatory changes in the utilities sector. Analyst sentiment is bullish with no sell ratings, indicating confidence in the company's long-term growth trajectory.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
